Novartis ESMO Event Presentation

PSMAfore analysis plan rPFS ㅏ OS PRIMARY ENDPOINT rPFS BICR per PCWG3/ RECIST v1.1 Primary Updated KEY SECONDARY ENDPOINT OS prespecified for RPSFT crossover-adjusted analysis 1st interim 2nd interim 3rd interim Other secondary endpoints rPFS2 ■ Time to soft tissue progression PFS, PFS2 PSA50 Time to SSE Time to chemotherapy ■ HRQoL Safety and tolerability 13 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION Exploratory endpoints ☐ ORR, DCR, DOR Time to PSA progression ■ Time to pain progression Biomarker associations Final NOVARTIS | Reimagining Medicine

View entire presentation